search
Back to results

Evaluation of the Auryzon Devices in the Optimization of Ear and Nose Reconstruction Procedures

Primary Purpose

Ear Deformities, Acquired, Ear; Deformity, Congenital, Microtia

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
AuryzoN Family of Devices
Sponsored by
Reconstrata, LLC
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Ear Deformities, Acquired

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients aged 1-100 of sufficient health required to undergo ear/nose reconstruction under general anesthesia
  • Pre-existing physical deformity of the ear, nose, or eyelid necessitating surgical reconstruction
  • Sufficient autologous or cadaveric rib cartilage for use by the AuryzoN system for cartilage processing

Exclusion Criteria:

  • Patients with ear/nose/eyelid deformities not requiring surgical correction
  • Patients without sufficient rib cartilage for use by the AuryzoN system and those who do not desire cadaveric cartilage use
  • Patients in poor health to undergo surgery under general anesthesia
  • Patients whose desired ear/nose/eyelid exceeds the dimensions/shapes of those pre-fabricated blades used in the AuryzoN system

Sites / Locations

  • Johns Hopkins HospitalRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Auryzon-Processed Ear/Nose

Arm Description

Patients in this category underwent reconstruction and implantation of a completed ear/nose cartilaginous graft that was processed using the AuryzoN device.

Outcomes

Primary Outcome Measures

Total cartilage processing time
Total operative time spent by the surgeon preparing cartilage substrate into finished structures
Objective Quality of Reconstruction
An objective scoring system will be developed to score ears and noses based on anatomic accuracy, and reconstructed ears/noses will be scored using this system. Scoring system scale: The following metrics will be assessed by independent observers on a scale from 0-5, with 5 indicating perfect anatomic fidelity as compared to the patient's contralateral ear (or a model ear if no contralateral ear is available) or model nose and 0 indicating complete anatomical difference or loss of that structure. The following ear and nose subcomponents will be graded: Ear: Helix, antihelix, tragus, crus, anatomical proportion of all substrates as compared to each other substrate. Nose: Septum, alar cartilages, lateral cartilages, horizontal strut, anatomical proportion of all substrates as compared to each other substrate.

Secondary Outcome Measures

Total operative time
Total operative time by the surgeon performing the reconstructive surgery
Cartilage processing error rate
Number of errors (defined as anatomic deviations) incurred during cartilaginous processing
Patient satisfaction
Subjective survey completed by patients asking about satisfaction with reconstruction
Subjective Quality of Reconstruction
Images of completed ear/nose reconstructions with the AuryzoN system will be presented to surgeons and lay-people to determine overall subjective quality of reconstruction

Full Information

First Posted
July 22, 2018
Last Updated
February 1, 2020
Sponsor
Reconstrata, LLC
Collaborators
Johns Hopkins University
search

1. Study Identification

Unique Protocol Identification Number
NCT03624608
Brief Title
Evaluation of the Auryzon Devices in the Optimization of Ear and Nose Reconstruction Procedures
Official Title
Evaluation of the Auryzon Family of Cartilage Processing Devices in the Optimization of Cartilaginous Reconstructions
Study Type
Interventional

2. Study Status

Record Verification Date
September 2019
Overall Recruitment Status
Recruiting
Study Start Date
March 1, 2020 (Anticipated)
Primary Completion Date
March 1, 2023 (Anticipated)
Study Completion Date
March 1, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Reconstrata, LLC
Collaborators
Johns Hopkins University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes

5. Study Description

Brief Summary
This study evaluates the efficacy of the AuryzoN devices in the ear and nose reconstruction surgeries, both in terms of operative time and overall quality of reconstruction. Research participants will undergo reconstruction either using the AuryzoN device or through current methods (traditional manual processing) at the discretion of their surgeon prior to the start of surgery.
Detailed Description
The AuryzoN devices are a family of two (2) devices that, in conjunction, serve to process substrates of autologous-derived or cadaveric cartilage used in the reconstruction of various structures of the body, namely ear and nose. The devices are to be used in the operating room to cut and carve substrates of tissue into components, which are then assembled into the final ear or nose, that will then be implanted by the plastic surgeon into the appropriate area. This device family serves to replace the current step in this reconstructive procedure, which involves the time-consuming and error-prone process of manual cartilage processing. Participants will be given the option to participate in the study. If the participants so choose, they will undergo ear or nose reconstruction using the AuryzoN devices or traditional manual processing at the discretion of their surgeon prior to the start of surgery. The following outcome measures will be measured: operative time, error rates, objective quality outcomes of reconstruction, subjective quality outcomes of reconstruction, and patient satisfaction.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Ear Deformities, Acquired, Ear; Deformity, Congenital, Microtia, Nose Deformity, Nose Deformities, Acquired, Nose; Deformity, Congenital, Nose; Deformity, Congenital, Bent or Squashed, Nose; Deformity, Syphilitic, Congenital, Nose; Deformity, Bone (Nose Cartilage), Nose; Deformity, Septum, Congenital, Nose; Deformity, Sinus (Wall), Congenital, Nose; Deformity, Syphilitic, Late (Etiology), Ear; Deformity, External, Ear; Deformity, Auricle, Ear, Acquired, Ear; Deformity, Auricle, Ear (Congenital)

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
100 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Auryzon-Processed Ear/Nose
Arm Type
Experimental
Arm Description
Patients in this category underwent reconstruction and implantation of a completed ear/nose cartilaginous graft that was processed using the AuryzoN device.
Intervention Type
Device
Intervention Name(s)
AuryzoN Family of Devices
Intervention Description
The AuryzoN family of devices includes a longitudinal cartilage trimmer (DimensioN) and 2D shape carving machine with custom blades (AuryzoN).
Primary Outcome Measure Information:
Title
Total cartilage processing time
Description
Total operative time spent by the surgeon preparing cartilage substrate into finished structures
Time Frame
Three years (until 2023)
Title
Objective Quality of Reconstruction
Description
An objective scoring system will be developed to score ears and noses based on anatomic accuracy, and reconstructed ears/noses will be scored using this system. Scoring system scale: The following metrics will be assessed by independent observers on a scale from 0-5, with 5 indicating perfect anatomic fidelity as compared to the patient's contralateral ear (or a model ear if no contralateral ear is available) or model nose and 0 indicating complete anatomical difference or loss of that structure. The following ear and nose subcomponents will be graded: Ear: Helix, antihelix, tragus, crus, anatomical proportion of all substrates as compared to each other substrate. Nose: Septum, alar cartilages, lateral cartilages, horizontal strut, anatomical proportion of all substrates as compared to each other substrate.
Time Frame
Up to 1 year post-op (until 2023)
Secondary Outcome Measure Information:
Title
Total operative time
Description
Total operative time by the surgeon performing the reconstructive surgery
Time Frame
Three years (until 2023)
Title
Cartilage processing error rate
Description
Number of errors (defined as anatomic deviations) incurred during cartilaginous processing
Time Frame
Three years (until 2023)
Title
Patient satisfaction
Description
Subjective survey completed by patients asking about satisfaction with reconstruction
Time Frame
Up to 1 year post-op (until 2023)
Title
Subjective Quality of Reconstruction
Description
Images of completed ear/nose reconstructions with the AuryzoN system will be presented to surgeons and lay-people to determine overall subjective quality of reconstruction
Time Frame
Up to 1 year post-op (until 2023)

10. Eligibility

Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients aged 1-100 of sufficient health required to undergo ear/nose reconstruction under general anesthesia Pre-existing physical deformity of the ear, nose, or eyelid necessitating surgical reconstruction Sufficient autologous or cadaveric rib cartilage for use by the AuryzoN system for cartilage processing Exclusion Criteria: Patients with ear/nose/eyelid deformities not requiring surgical correction Patients without sufficient rib cartilage for use by the AuryzoN system and those who do not desire cadaveric cartilage use Patients in poor health to undergo surgery under general anesthesia Patients whose desired ear/nose/eyelid exceeds the dimensions/shapes of those pre-fabricated blades used in the AuryzoN system
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Angelo Leto Barone
Phone
6672240758
Email
aletobarone@reconstrata.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Angelo Leto Barone
Organizational Affiliation
Reconstrata, LLC
Official's Role
Principal Investigator
Facility Information:
Facility Name
Johns Hopkins Hospital
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21287
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Angelo Leto Barone, MD

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Citations:
PubMed Identifier
33185490
Citation
Leto Barone AA, Arun A, Samaha GJ, Shallal CC, Redett RJ, Steinberg JP. Design of a Novel Reproducible Cartilage-Sparing Autologous Technique for Microtia Repair. Facial Plast Surg Aesthet Med. 2021 May-Jun;23(3):224-229. doi: 10.1089/fpsam.2020.0457. Epub 2020 Nov 12.
Results Reference
derived

Learn more about this trial

Evaluation of the Auryzon Devices in the Optimization of Ear and Nose Reconstruction Procedures

We'll reach out to this number within 24 hrs